Ann Pediatr Endocrinol Metab.  2015 Jun;20(2):69-73. 10.6065/apem.2015.20.2.69.

Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus

• Kim MS
• Lee DY

• KMID: 2368988
• DOI: http://doi.org/10.6065/apem.2015.20.2.69

Abstract

Increasing evidence suggests an important role of the insulin-like growth factor (IGF)-IGF binding protein (IGFBP) axis in the maintenance of normal glucose and lipid metabolism. Significant changes occur in the local IGF-I-IGFBPs environment in response to the diabetic milieu. A significant reduction of serum IGF-I levels was observed in patients with type 1 diabetes mellitus (T1DM). Inversely, considerably increased serum levels of IGF-I and IGFBP-3 levels were detected in individuals with glucose intolerance including T2DM. Recently, several prospective studies indicated that baseline levels of IGF-I and IGFBPs are associated with the development of diabetes. These findings suggest that disturbances in insulin and IGF-I-IGFBP axis can affect the development of glucose intolerance including diabetes.

Keyword

Diabetes mellitus; Insulin-like growth factor I; Insulin-like growth factor binding protein 1; Insulin-like growth factor binding protein 3; Lipid metabolism

MeSH Terms

Axis*
Carrier Proteins
Diabetes Mellitus*
Diabetes Mellitus, Type 1
Glucose
Glucose Intolerance
Humans
Insulin
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Proteins*
Insulin-Like Growth Factor I
Lipid Metabolism
Carrier Proteins
Glucose
Insulin
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor I

Reference

1. Daughaday WH. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology. 1990; 127:1–4. PMID: 2163304.

2. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5:2503–2512. PMID: 2877871.

3. Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol. 2006; 6:620–625. PMID: 17030015.

4. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997; 336:633–640. PMID: 9032050.

5. Baxter RC, Martin JL. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res. 1989; 1:49–68. PMID: 2485012.

6. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995; 16:3–34. PMID: 7758431.

7. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009; 30:417–437. PMID: 19477944.

8. Walker GE, Kim HS, Yang YF, Oh Y. IGF-independent effects of the IGF superfamily. In : Le Roith D, Zumkeller W, Baxter R, editors. Insulin-like growth factors. Austin (Tx): Landes Biosciences;2004. p. 1–22.

9. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996; 45:91–100. PMID: 8522066.

10. Scavo LM, Karas M, Murray M, Leroith D. Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. J Clin Endocrinol Metab. 2004; 89:3543–3553. PMID: 15240644.

11. Laager R, Ninnis R, Keller U. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J Clin Invest. 1993; 92:1903–1909. PMID: 8408642.

12. Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. J Clin Invest. 1989; 83:1717–1723. PMID: 2651479.

13. Sesti G, Sciacqua A, Cardellini M, Marini MA, Maio R, Vatrano M, et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care. 2005; 28:120–125. PMID: 15616244.

14. Russell-Jones DL, Bates AT, Umpleby AM, Hennessy TR, Bowes SB, Hopkins KD, et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest. 1995; 25:403–411. PMID: 7656918.

15. Katz LE, DeLeon DD, Zhao H, Jawad AF. Free and total insulin-like growth factor (IGF)-I levels decline during fasting: relationships with insulin and IGF-binding protein-1. J Clin Endocrinol Metab. 2002; 87:2978–2983. PMID: 12050283.

16. Luo J, Murphy LJ. Differential expression of the insulin-like growth factor binding proteins in spontaneously diabetic rats. J Mol Endocrinol. 1992; 8:155–163. PMID: 1381181.

17. Lang CH, Vary TC, Frost RA. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology. 2003; 144:3922–3933. PMID: 12933666.

18. Manetta J, Brun JF, Maimoun L, Callis A, Prefaut C, Mercier J. Effect of training on the GH/IGF-I axis during exercise in middle-aged men: relationship to glucose homeostasis. Am J Physiol Endocrinol Metab. 2002; 283:E929–E936. PMID: 12376319.

19. Muzumdar RH, Ma X, Fishman S, Yang X, Atzmon G, Vuguin P, et al. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes. 2006; 55:2788–2796. PMID: 17003344.

20. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem. 2000; 275:23462–23470. PMID: 10811646.

21. Silha JV, Gui Y, Murphy LJ. Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice. Am J Physiol Endocrinol Metab. 2002; 283:E937–E945. PMID: 12376320.

22. Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K, et al. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2002; 282:E1360–E1368. PMID: 12006367.

23. Laager R, Keller U. Effects of recombinant human insulin-like growth factor I and insulin on counterregulation during acute plasma glucose decrements in normal and type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1993; 36:966–971. PMID: 8243878.

24. Turkalj I, Keller U, Ninnis R, Vosmeer S, Stauffacher W. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab. 1992; 75:1186–1191. PMID: 1430077.

25. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004; 89:114–120. PMID: 14715837.

26. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 2002; 359:1740–1745. PMID: 12049864.

27. Dunger DB, Cheetham TD, Holly JM, Matthews DR. Does recombinant insulin-like growth factor I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence? Acta Paediatr Suppl. 1993; 388:49–52. PMID: 8329831.

28. Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol. 1991; 260(6 Pt 1):E846–E851. PMID: 2058660.

29. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994; 79:872–878. PMID: 7521354.

30. Holt RI, Simpson HL, Sonksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med. 2003; 20:3–15. PMID: 12519314.

31. Murphy LJ. The role of the insulin-like growth factors and their binding proteins in glucose homeostasis. Exp Diabesity Res. 2003; 4:213–224. PMID: 14668045.

32. Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 2009; 25:3–12. PMID: 19145587.

33. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999; 15:314–322. PMID: 10585616.

34. Rajpathak SN, He M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, et al. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 2012; 61:2248–2254. PMID: 22554827.

35. Munoz MT, Barrios V, Pozo J, Argente J. Insulin-like growth factor I, its binding proteins 1 and 3, and growth hormone-binding protein in children and adolescents with insulin-dependent diabetes mellitus: clinical implications. Pediatr Res. 1996; 39:992–998. PMID: 8725260.

36. Gambaro G, Baggio B. Growth factors and the kidney in diabetes mellitus. Crit Rev Clin Lab Sci. 1998; 35:117–151. PMID: 9592624.

37. Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is negatively associated with serum adiponectin in type 2 diabetes mellitus. Growth Horm IGF Res. 2011; 21:268–271. PMID: 21839662.

38. Dunger DB, Regan FM, Acerini CL. Childhood and adolescent diabetes. Endocr Dev. 2005; 9:107–120. PMID: 15879693.

39. Cinaz P, Kendirci M, Kurtoglu S, Gokcora N, Buyan N, Yavuz I, et al. Serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in children with insulin-dependent diabetes mellitus. J Pediatr Endocrinol Metab. 1996; 9:475–482. PMID: 8910817.

40. Wedrychowicz A, Dziatkowiak H, Nazim J, Sztefko K. Insulin-like growth factor-1 and its binding proteins, IGFBP-1 and IGFBP-3, in adolescents with type-1 diabetes mellitus and microalbuminuria. Horm Res. 2005; 63:245–251. PMID: 15920342.

41. Bereket A, Lang CH, Blethen SL, Fan J, Frost RA, Wilson TA. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab. 1995; 80:2282–2288. PMID: 7543110.

42. Kim MS, Lee DY. Serum insulin-like growth factor-binding protein-3 level correlated with glycemic control and lipid profiles in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2014; 27:857–861. PMID: 24825082.

43. Payne JF, Tangpricha V, Cleveland J, Lynn MJ, Ray R, Srivastava SK. Serum insulin-like growth factor-I in diabetic retinopathy. Mol Vis. 2011; 17:2318–2324. PMID: 21921983.

44. Kim MS, Hwang PH, Lee DY. Clinical characteristics of type 2 diabetes in children identified by school urine glucose screening [abstract]. In : Program and Abstract, the 8th Congress of Asian Society for Pediatric Research; 2012 May 17-19; Seoul, Korea. Seoul: Asian Society for Pediatric Research;2012. p. 180.